Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone | Zendy

Gabriel N. Hortobágyi | Zendy; Catherine Van Poznak | Zendy; W G Harker | Zendy; William J. Gradishar | Zendy; Helen K. Chew | Zendy; Shaker R. Dakhil | Zendy; Barbara Haley | Zendy; Nicholas Sauter | Zendy; Ramon Mohanlal | Zendy; Ming Zheng | Zendy; Allan Lipton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone

Author(s) -

Gabriel N. Hortobágyi,

Catherine Van Poznak,

W G Harker,

William J. Gradishar,

Helen K. Chew,

Shaker R. Dakhil,

Barbara Haley,

Nicholas Sauter,

Ramon Mohanlal,

Ming Zheng,

Allan Lipton

Publication year - 2017

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2016.6316

Subject(s) - zoledronic acid , medicine , breast cancer , bisphosphonate , randomized controlled trial , regimen , denosumab , clinical endpoint , metastatic breast cancer , surgery , dosing , bone metastasis , interim analysis , osteoporosis , cancer

Zoledronic acid, a potent bisphosphonate, is commonly administered to patients with bone metastases to reduce the risk of skeletal-related events (SREs). However, there have been concerns regarding its long-term monthly administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research